PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population

被引:0
作者
Marta Herreros-Villanueva
Noemí Gomez-Manero
Pilar Muñiz
Carlos García-Girón
Maria Jesús Coma del Corral
机构
[1] Hospital General Yagüe,Unidad de Investigación
[2] Hospital General Yagüe,Servicio de Medicina Interna
[3] Universidad de Burgos,Departamento de Bioquímica
[4] Hospital General Yagüe,Servicio de Oncología
来源
Molecular Biology Reports | 2011年 / 38卷
关键词
Cetuximab; Colorectal cancer;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of the work was to study PIK3CA mutations in wild type KRAS and BRAF colorectal cancer. Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yagüe Hospital in Burgos. KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in all patients. PIK3CA mutations were present in 8.22% of wild type KRAS and BRAF colorectal cancers. The most frequent mutation is E545K/D in exon 9 which represents 83.3% of all mutations. By contrast, we did not found any tumour harbouring H1047R mutation in exon 20. Among the patients who undergo a curative resection of colorectal cancer, PIK3CA mutation is present in an important percentage of KRAS and BRAF wild type tumours. PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies.
引用
收藏
页码:1347 / 1351
页数:4
相关论文
共 96 条
[1]  
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]  
Siegel R(2010)The molecular therapy of colorectal cancer Mol Aspects Med 31 171-178
[3]  
Ward E(2007)First-line treatment strategies for elderly patients with metastatic colorectal cancer Drugs Aging 24 223-238
[4]  
Waldner MJ(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
[5]  
Neurath MF(2007)Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 1658-1664
[6]  
Meulenbeld HJ(2005)ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341-354
[7]  
Creemers GJ(2006)Epidermal growth factor receptor targeting in cancer Semin Oncol 33 369-385
[8]  
Cunningham D(2003)Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 11-22
[9]  
Humblet Y(2003)RAS oncogenes: the first 30 years Nat Rev Cancer 3 459-465
[10]  
Siena S(2007)Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 295-308